Bone marrow response to ATO in patients (n=13) with APL
| . | Patients evaluated, no. . | Patients achieving CR, no. . | APL patients with CR, % of enrolled . | Median doses to achieve CR, no. (range) . |
|---|---|---|---|---|
| Morphological | 13 | 11 | 85 | 20 (17-20) |
| Cytogenetic | 11 | 9 | 69* | 50 (20-70) |
| Molecular | 7 | 3 | 23* | 70 (40-70) |
| . | Patients evaluated, no. . | Patients achieving CR, no. . | APL patients with CR, % of enrolled . | Median doses to achieve CR, no. (range) . |
|---|---|---|---|---|
| Morphological | 13 | 11 | 85 | 20 (17-20) |
| Cytogenetic | 11 | 9 | 69* | 50 (20-70) |
| Molecular | 7 | 3 | 23* | 70 (40-70) |
Cytogenetic and molecular response evaluations were not required or performed in all APL patients. The response rate is calculated from number of enrolled APL patients (n=13). The number of patients evaluated by each method is listed in column 1.